Hemodynamic parameters and collagen content.

<p>SBP, systolic blood pressure; DBP, diastolic blood pressure; LVEDP, left ventricular end-diastolic pressure; LVSP, left ventricular systolic pressure, HR, heart rate; +dP/dt the first derivative of LV pressure rise over time; –dP/dt, the first derivative of LV pressure decline over time. HW/BW; heart weight/100 g body weight.</p><p>*p&lt;0.05 vs CONTROL;</p>†<p>p&lt;0.05 vs ALDO.</p><p>Hemodynamic parameters and collagen content.</p

Primers sequences.

<p>GeneBank accession numbers: 18S NR045132.1, CTGF AC127189.4, TGF-β NM021578.2, MMP-2 BC074013.1, TIMP-2 BC084714.1, IL-1β, NG008851.1, TNF-α NM012675.3, eNOS NM021838.2, p22phox NM024160.1 and SGK-1 NM001193569.1.</p><p>Primers sequences.</p

Effect of P4 individual fractions on aldosterone-induced human mineralocorticoid receptor (hMR) transcriptional activity.

<p>CV-1 cells transfected with hMR expression and MMTV-LUC reporter plasmids were treated with vehicle (V) or aldosterone 1 nM (A1 nM) in presence of spironolactone 100 nM (S100 nM) or fractions (F) 31 to 40 (1 µM), blank (B) and blank+aldosterone1 nM (B+A1 nM). Each data point represents the mean ± SEM derived from 3 independent experiments. *p&lt;0.01 vs V; ^†p&lt;0.05 <i>vs.</i> A1 nM.</p

TGF-β (A), CTGF (B), MMP2 (C), TIMP2 (D) mRNA levels, and MMP2/TIMP2 ratio (E) in control (C), aldosterone-salt-treated animals (ALDO), PASE (PASE), aldosterone-salt plus PASE treated animals (ALDO+PASE), spironolactone treated animals (SPIRO) and aldoste

<p>Data are expressed as mean ± SEM derived from 8 animals per group. *p&lt;0.05 <i>vs</i>. C; ^†p&lt;0.05 <i>vs</i>. ALDO.</p

HPLC chromatogram and pools representation.

<p>Column: Waters Novapak C18 60Å 4 µm, 30×0.39 cm. Flow rate = 1 ml/min. Buffer A: 2% CH3COOH. Buffer B: 2% CH3COOH, 25% CH3CN. Arrow indicates column strip with 2% CH3COOH, 75% CH3CN. Sample volume loaded = 1 ml. Fractions collected at 1 min intervals. Pools compound of 10 individual fractions; P1∶1–10, P2∶11–20, P3∶21–30. P4∶31–40, P5∶41–50, P6∶51–60, P7∶61–70, P8∶71–80, P9∶81–90 and P10∶91–100.</p

TNF-α (A), IL-1β (B), p22phox (C) and eNOS (D) mRNA levels in control (C), aldosterone-salt-treated animals (ALDO), PASE (PASE), aldosterone-salt plus PASE treated animals (ALDO+PASE), spironolactone treated animals (SPIRO) and aldosterone-salt plus spiro

<p>Data are expressed as mean ± SEM derived from 8 animals per group. *p&lt;0.05 <i>vs</i>. C; ^†p&lt;0.05 <i>vs</i>. ALDO.</p

Effect of PASE on aldosterone-induced human mineralocorticoid receptor (hMR) transcriptional activity.

<p>CV-1 cells transfected with hMR expression and MMTV-LUC reporter plasmids were treated with vehicle (V) or aldosterone 1 nM (A1 nM) in presence of spironolactone 100 nM (S100 nM) or PASE 10 nM, 100 nM or 1 µM (P10 nM, P100 nM or P1 µM). Each data point represents the mean ± SEM derived from 3 independent experiments. *p&lt;0.01 vs V; ^†p&lt;0.05 <i>vs.</i> A1 nM.</p

SGK-1 mRNA levels in control (C), aldosterone treated animals (ALDO), PASE (PASE), aldosterone plus PASE treated animals (ALDO+PASE), spironolactone treated animals (SPIRO) and aldosterone-salt plus spironolactone (ALDO+SPIRO).

<p>Data are expressed as mean ± SEM derived from 8 animals per group. *p&lt;0.05 <i>vs.</i> CONTROL; ^†p&lt;0.05 <i>vs.</i> ALDO.</p

Psychologické a sociální aspekty umírání a smrti

<p>Data are expressed as mean ± SEM. *p<0.05 vs. CONTROL; ^#p<0.05 vs. ALDO</p

Quantitative analyses of protein levels measured by Western blot for ColI (A), FN (B), CTGF (C) and MMP-2(D) in control (CONTROL), spironolactone treated animals (SPIRO), aldosterone+salt-treated animals (ALDO) and aldosterone+salt plus spironolactone treated animals (ALDO+SPIRO).

<p>Data are expressed as mean ± SEM. *p<0.05 vs. CONTROL; ^#p<0.05 vs. ALDO</p